OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

June 27th 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

Dr. Lunning on the FDA Approval of Liso-cel in LBCL

June 24th 2022

Matthew A. Lunning, DO, FACP, discusses how the FDA approval of lisocabtagene maraleucel expands treatment options for patients with large B-cell lymphoma.

Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer

June 24th 2022

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

Dr. Nakayama on the Current Treatment Landscape of Ovarian Cancer

June 24th 2022

John Nakayama, MD, discusses the current treatment landscape of ovarian cancer and where he hopes the field advances in the future.

Dr. Khorana on Rates of Young-Onset Pancreatobiliary Adenocarcinoma

June 24th 2022

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

June 24th 2022

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Dr. Kamath on the Inclusion of Underrepresented Groups in Clinical Trials

June 24th 2022

Suneel Kamath, MD, discusses the importance of including underrepresented patient populations in clinical trials.

Dr. Tawbi on the Safety of Relatlimab Plus Nivolumab in Melanoma

June 24th 2022

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

Dr. Carraway on the Importance of Testing for Biomarkers in Patients with MDS and AML

June 23rd 2022

Hetty Carraway, MD, discusses the role of biomarker testing in patients with myelodysplastic syndromes and acute myeloid leukemia.

Dr. Spira on the CNS Activity of Adagrasib in NSCLC

June 23rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the activity of adagrasib in patients with non–small cell lung cancer and central nervous system metastases.

Dr. Monk on Platinum Ineligibility and Emerging ADCs in Ovarian Cancer

June 23rd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the role platinum-based chemotherapy in recurrent ovarian cancer, plus emerging antibody-drug conjugates in the space.

Dr. DeAngelo on Rates of CRS with Obe-cel in ALL

June 22nd 2022

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

Dr. Krishnan of the Effectiveness of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 22nd 2022

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid Tumors

June 20th 2022

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

Dr. Sandhu on the Design of the MAGNITUDE trial in Prostate Cancer

June 20th 2022

Shahneen Sandhu, MD, discusses the design of the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Dr. Gupta on the Methodologies of the PARADIGM Study in Urothelial Cancer

June 20th 2022

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Wenham on the Role of ADCs in Ovarian Cancer

June 20th 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Dr. Matulonis on the Current Treatment Landscape of Recurrent Ovarian Cancers

June 20th 2022

Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.